ABOS on Nasdaq
Acumen Pharmaceuticals, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $104.9M | $93.8M |
| General and administrative | $18.9M | $20.2M |
| Total operating expenses | $123.8M | $114.0M |
| Loss from operations | -$123.8M | -$114.0M |
| Interest income | $7.4M | $14.3M |
| Interest expense | -$4.2M | -$4.1M |
| Change in fair value of embedded derivatives | -$460.0K | $1.6M |
| Other expense, net | -$266.0K | -$151.0K |
| Total other income | $2.5M | $11.7M |
| Net loss | -$121.3M | -$102.3M |
| Unrealized gain (loss) on marketable securities | $131.0K | -$360.0K |
| Comprehensive loss | -$121.2M | -$102.7M |
| Net loss per common share, basic (in dollars per share) | -$2.00 | -$1.71 |
| Net loss per common share, diluted (in dollars per share) | -$2.00 | -$1.71 |
| Weighted-average shares outstanding, basic (in shares) | 60.6M shares | 60.0M shares |
| Weighted-average shares outstanding diluted (in shares) | 60.6M shares | 60.0M shares |
Every line of the balance sheet in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $54.0M | $35.6M | |
| Marketable securities, short-term | $62.9M | $135.9M | |
| Prepaid expenses and other current assets | $5.4M | $6.7M | |
| Total current assets | $122.3M | $178.3M | |
| Marketable securities, long-term | $0 | $60.0M | |
| Restricted cash | $231.0K | $232.0K | |
| Other assets, long-term | $350.0K | $486.0K | |
| Total assets | $122.8M | $239.0M | |
| Accounts payable | $554.0K | $5.6M | |
| Accrued clinical trial expenses | $10.6M | $15.3M | |
| Accrued expenses and other current liabilities | $10.1M | $6.6M | |
| Debt, short-term | $8.8M | $0 | |
| Total current liabilities | $30.0M | $27.6M | |
| Debt, long-term | $22.4M | $29.4M | |
| Other liabilities, long-term | $0 | $150.0K | |
| Total liabilities | $52.4M | $57.2M | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024; 60,575,369 and 60,094,083 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $6.0K | $6.0K | |
| Additional paid-in capital | $516.8M | $507.0M | |
| Accumulated deficit | -$446.5M | -$325.1M | |
| Accumulated other comprehensive income (loss) | $83.0K | -$48.0K | |
| Total stockholders equity | $70.4M | $181.8M | $267.0M |
| Total liabilities and stockholders equity | $122.8M | $239.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | |
| Common stock, shares issued (in shares) | 60.6M shares | 60.1M shares | |
| Common stock, shares outstanding (in shares) | 60.6M shares | 60.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$121.3M | -$102.3M |
| Depreciation | $58.0K | $63.0K |
| Stock-based compensation expense | $9.9M | $9.6M |
| Amortization of premiums and accretion of discounts on marketable securities, net | -$809.0K | -$5.0M |
| Change in fair value of embedded derivatives | $460.0K | -$1.6M |
| Amortization of right-of-use asset | $126.0K | $115.0K |
| Realized gain on marketable securities | -$59.0K | -$97.0K |
| Noncash interest expense | $1.3M | $1.1M |
| Other noncash expense | $0 | $232.0K |
| Prepaid expenses and other current assets | $1.4M | -$3.7M |
| Other long-term assets | $40.0K | $74.0K |
| Accounts payable | -$5.1M | $4.3M |
| Accrued clinical trial expenses | -$4.7M | $11.0M |
| Accrued expenses and other liabilities | $3.3M | $32.0K |
| Finance lease liability | $0 | -$23.0K |
| Net cash used in operating activities | -$115.5M | -$86.2M |
| Purchases of marketable securities | -$38.1M | -$170.7M |
| Proceeds from maturities and sales of marketable securities | $172.1M | $218.8M |
| Purchases of property and equipment | -$88.0K | -$16.0K |
| Net cash provided by investing activities | $133.9M | $48.0M |
| Proceeds from issuance of common stock, net of issuance costs | $0 | $7.9M |
| Proceeds from exercise of stock options | $39.0K | $0 |
| Payment for financing lease | $0 | -$739.0K |
| Payments for deferred offering costs | $0 | -$230.0K |
| Repurchase of common shares to pay employee withholding taxes | -$73.0K | -$41.0K |
| Net cash (used in) provided by financing activities | -$34.0K | $6.9M |
| Net change in cash and cash equivalents and restricted cash | $18.4M | -$31.3M |
| Cash paid for income taxes | $0 | $0 |
| Cash paid for interest | $2.9M | $3.0M |
Recent filings
- Sep 16, 20268-K
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Aug 12, 2026S-8
- Jun 17, 2026144
- Jun 17, 20264
- Jun 16, 20268-K
- Jun 16, 2026144
- Jun 15, 2026144
- Jun 10, 20264
- Jun 9, 2026144
- Jun 5, 20264
- Jun 5, 20264
- Jun 5, 20264
- Jun 5, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9